Olema Pharmaceuticals, Inc. · NASDAQ:OLMA
Raymond Debbane reported a 5.10% stake in Olema Pharmaceuticals, Inc. (Schedule 13G)
Event Mar 16, 2026 · Filed Mar 20, 2026
Raymond Debbane reported a 5.10% stake in Olema Pharmaceuticals, Inc., 4,461,949 shares, as a passive investor on Mar 16, 2026. Filed Mar 20, 2026 (Schedule 13G).
- Stake
- 5.10%
- Shares
- 4,461,949
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Invus Public Equities, L.P. | 4.50% | 3,898,500 |
| Invus Public Equities Advisors, LLC | 4.50% | 3,898,500 |
| Invus Global Management, LLC | 4.50% | 3,898,500 |
| Siren, L.L.C. | 4.50% | 3,898,500 |
| Avicenna Life Sci Master Fund LP | 0.60% | 563,449 |
| Avicenna Life Sci Master GP LLC | 0.60% | 563,449 |
| Ulys, L.L.C. | 0.60% | 563,449 |
| Raymond Debbane | 5.10% | 4,461,949 |
Source
Related
- Olema Pharmaceuticals, Inc.
- Invus Public Equities, L.P.
- Olema Pharmaceuticals, Inc. shareholders
- Schedule 13D/A · Bvf Partners L P · Oct 16, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 29, 2026
- Form 4 · Harmon Cyrus · Jul 27, 2026
- Schedule 13G/A · Bain Capital Life Sciences Opportunities IV, L.P. · May 15, 2026